Â鶹ÊÓƵ

GSK doubles down on oncology as AstraZeneca’s pipeline cranks up

Executive pay and patent cliffs give clues to the future ahead of the pharma giants’ first-quarter results

Renewable investment trusts hit by wave of policy changes

Government intervention after a surge in power prices could prove a mixed blessing for the sector

ASML faces new squeeze as US targets chip war loopholes

A new bipartisan act across the Atlantic puts the Dutch giant at the centre of a deepening US-China tech divide

Can Spire Healthcare’s strategic review revive its share price?

With private equity bidders retreating, the board has three primary paths to drive shareholder value

Will renewable trusts benefit from higher energy prices?

Rising power prices will be felt unevenly, with some funds more exposed than others

The bond funds proving their worth

A surprising outcome in the bond market has fund managers split on what happens next

Standard Life snaps up Aegon UK in £2bn deal

Creates a new group with 16mn customers and £480bn of assets

Should insurer shareholders worry about private credit?

European insurers have pure private credit in their portfolios, and investors are becoming wary of spillover

Can gambling stocks move on from the prediction market sell-off?

Analysts point to resilience in regulated markets and question how much damage new rivals can really do

AI offers new revenue for media stocks – but at what cost?

The new tech has hit publishers’ profits hard, but there are ways to take advantage